Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Inclusion Criteria:

• Able to be dosed in both eyes, able and willing to make the required study visits andto follow instructions.

• Negative urine pregnancy test if female of childbearing potential and use adequatebirth control throughout the study period.

• Diagnostic skin test indicative of allergy for cat hair, cat dander, grasses, ragweed,dust mite, dog dander, cockroach and/or trees within 24 months prior to Visit 1 or atVisit 1.

• History of seasonal or perennial allergic conjunctivitis for at least 1 year prior toVisit 1.

• Best-corrected visual acuity of 55 or greater in each eye as measured by ETDRS (letters read method).

• Manifest a positive bilateral Conjunctival Allergen Challenge (CAC) test response.

• Willing to discontinue contact lens wear for at least 72 hours prior to Visit 1 andthroughout the study.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Known history or presence of persistent dry eye syndrome, or currently requiresfrequent use of artificial tears, gels or lubricants, presence of punctal plugs, useof Restasis®, or topical ocular corticosteroids for dryness of eyes.

• Presence of an ocular condition that may affect the study outcomes.

• History or evidence of ocular surgery (including refractive procedures such as LASIK,PRK and RK) within 6 months of Visit 1.

• Presence of signs/symptoms of active allergic conjunctivitis at the start of Visits 1, 2, 3A, or 4.

• History of anaphylactic reaction to any allergens used in this study.

• Current evidence or recent (within 6 months) history of severe, unstable, oruncontrolled medical conditions and/or other relevant systemic diseases.

• Use of any disallowed medication without protocol-specified washout period prior toVisit 1, or during the study.

• Other protocol-defined exclusion criteria may apply.